Navigation Links
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
Date:3/12/2009

t. Other key endpoints of the study include imaging assessments by angiography, IVUS, OCT, and other state-of-the-art invasive and non-invasive imaging modalities at six and 18 months, and at one or two years.

About XIENCE V

Abbott's market-leading XIENCE V(TM) Everolimus Eluting Coronary Stent System was approved by the U.S. Food and Drug Administration and launched in July 2008, and was launched in Europe and other international markets in October 2006. XIENCE V is an investigational device in Japan and is currently under review by the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency.

Additional information about XIENCE V, including important safety and effectiveness information, is available online at www.xiencev.com.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical produ
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
2. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
3. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
4. TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
5. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
6. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
7. Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers Diarrhea Vaccine
8. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
9. SurgiLance Safety Lancet Part of Major HIV Testing Initiative in Sub-Saharan Africa
10. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
11. New Data Published in The Lancet Show GSKs ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 According ... by Composition of Material, Application (Healthcare, Homeland security, ... Product (Personal Instrument, Hand-Held Instruments, Fixed, and Installed ... to 2013 - 2020", published by MarketsandMarkets, the Scintillator Market ... 5.62% from 2014 to 2020, and reach $479.16 ...
(Date:7/11/2014)...  Kindred Hospital Houston Northwest, with Wound Care ... its new outpatient wound healing center.  The wound ... chronic, hard to heal wounds. Chronic wounds include ... lower leg wounds related to blood flow issues, ... injury wounds which are complex and demonstrate delayed ...
(Date:7/11/2014)... 2014 On Thursday, July ... the Dow Jones Industrial Average finished the day 0.42% lower ... 0.41%. The losses were broad based as eight out of ... Health Care Sector Index ended the day at 711.88, down ... one month. Investor-Edge has initiated coverage on the following equities: ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4
... HeartSine Technologies received the Outstanding Achievement in Business ... 25th, in Belfast, Northern Ireland. The award honors an ... and surrounding communities. The Aisling Award was ... 1997 to honor champions and ambassadors from every field ...
... (Nasdaq: ELGX ), developer of minimally invasive ... Managing Director at Essex Woodlands Health Ventures, has joined ... majority shareholder of Nellix Inc, which was acquired by ... 2010. In conjunction with the acquisition, Essex Woodlands made ...
Cached Medicine Technology:HeartSine Technologies Wins 2010 Aisling Award for Outstanding Achievement in Business 2Endologix Appoints Guido Neels to Its Board of Directors 2Endologix Appoints Guido Neels to Its Board of Directors 3
(Date:7/11/2014)... The American Association of Poison Control ... are commending Senator Bill Nelson (D-FL) for his introduction ... on July 10, 2014. Along with fellow Senate co-sponsors, ... (CPSC) to enact rules requiring safer, child-resistant packaging for ... Senate co-sponsors of the bill include: Sen. Richard Blumenthal ...
(Date:7/11/2014)... Ticket Down reports that tickets to the Argentina ... Cup Match between Brazil and Netherlands are in ... Saturday, July 12th at Estadio Nacional de Brasilia Mane Garrincha ... on Sunday, July 13th at Estadio Jornalista Mario Filho - ... 2014 World Cup are guaranteed to be authentic and are ...
(Date:7/11/2014)... Butler Mobility has recently updated the paint color choices for ... the two standard colors were beige and brown. Butler ... standard colors at no additional charge! These colors will ... the beauty of the stairway. Homeowners will find a ... décor. , The new selection of standard colors is: , ...
(Date:7/11/2014)... the lowest incomes may have a higher risk for a ... suggests. People with PAD have narrowing of the arteries ... The condition causes leg pain and is often an indicator ... PAD have a higher risk for heart disease and stroke. ... who took part in the U.S. National Health and Nutrition ...
(Date:7/11/2014)... Volunteers from Scientology Churches ... week with drug education lectures, forums and conferences, information ... cities around the world. , Drug abuse is an ... Drug Abuse, abuse of alcohol and illicit drugs costs ... work, decreased productivity and healthcare. , In the ...
Breaking Medicine News(10 mins):Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3
... ... Group in Boston, at The Liberty Hotel today, which for the first time includes ... to connect and exchange data with other applications. , ... Boston, Massachusetts (Vocus) October 20, 2009 -- ...
... RICHMOND, Calif., Oct. 20 ... the presentation of top-line, statistically significant Phase 2 clinical ... as a treatment for diabetic neuropathy (DN) at the ... Top-line data from Sangamo,s SB-509-601 Phase 2 clinical trial ...
... 20 In testimony to a U.S. House of ... ways to better meet the needs of every community ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) , Trevor Riggen, Red ... to how the Red Cross is meeting the needs ...
... advanced liver disease who drink three or more cups of ... disease progression than non-coffee drinkers according to a new study ... Institute (NCI). The study found that patients with hepatitis ... standard disease treatment benefited from increased coffee intake. An ...
... Sponsor Event to Earn the World Record for the Most Massages ... On Sunday, October 25, Massage Envy will sponsor an event ... massaged simultaneously in one location. The goal is to have ... 34th annual Marine Corps Marathon. There will be a sea ...
... (HCC) or primary liver cancer forms in the epithelial tissue ... hepatitis B virus (HBV) or hepatitis C virus (HCV). ... 15,000 men and 6,000 women are diagnosed with HCC each ... highest regions being Western Pacific and Africa according to a ...
Cached Medicine News:Health News:Orion Health™ Rhapsody User Group 2009, Boston Starts Today,New Interoperability Expo Helps Ignite Record Attendance 2Health News:Orion Health™ Rhapsody User Group 2009, Boston Starts Today,New Interoperability Expo Helps Ignite Record Attendance 3Health News:Orion Health™ Rhapsody User Group 2009, Boston Starts Today,New Interoperability Expo Helps Ignite Record Attendance 4Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 2Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 3Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 4Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 5Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 6Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 7Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 8Health News:Red Cross Strives to Help Disaster's Vulnerable Population 2Health News:Red Cross Strives to Help Disaster's Vulnerable Population 3Health News:Drinking coffee slows progression of liver disease in chronic hepatitis C sufferers 2Health News:Record-Breaking Relaxation at Marine Corps Marathon 2Health News:Scientists identify specific markers that trigger aggressiveness of liver cancer 2
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
... The Wet-Field Coagulator provides precise episcleral, ... peripheral tissue trauma. Controlled Rf diathermy ... comprehensive line of bipolar Eraser instruments, ... enhanced features that ensure a high ...
Medicine Products: